{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"4725.8","value":"4429.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1283"}],"units":"Participants"}],"description":"Objective 4: To describe hematological outcomes observed in association with primary and secondary prophylactic use of EP2006 in patients at risk for FN; including break-through episodes of FN.","dispersionType":"Standard Deviation","groups":[{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG000","title":"EP2006"}],"paramType":"MEAN","populationDescription":"Number of patients in evaluable sample with initial ANC result","reportingStatus":"POSTED","timeFrame":"Enrollment cycle. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician.","title":"Absolute Neutrophil Count (ANC) at EP2006 Initiation","type":"PRIMARY","unitOfMeasure":"Per mm^3"}